HOME - Clinical cases - Oral surgery
 
 
03 July 2019

Odontogenic keratocysts: analysis of recurrence

Lara Figini


Odontogenic keratocyst (OKC), also known as keratoconus odontogenic tumor, is locally aggressive and frequently relapses, with most relapses occurring within 5 years of treatment. It originates from the epithelial tissue residues that participate in tooth formation (dental lamina). It can be uni- or multilocular, it has an invasive growth, and it tends to expand inside the bone tissue, inducing its reabsorption. If not diagnosed and treated it can lead to deformation of the affected bone and soft tissue, cause pain, tooth displacement, paresthesia and anesthesia due to nerve compression.
The treatment is mainly surgical, and involves the removal of the lesion, followed by a careful remote follow-up.  

MATERIALS AND METHODS
The study published by Kinard et al. investigated the overall percentage of recurrence of odontogenic keratocysts 5 years after treatment and what factors were associated with their recurrence.This multicenter retrospective cohort study considered patients for the evaluation and management of OKC previously never treated for this issue. The predictive variables have been grouped into demographic, medical, radiographic and operational categories. The primary outcome variable was represented by the recurrence time of the lesion. Data analyzes were performed using bivariate analysis and univariate or multivariate Cox proportional risk models. 

RESULTS
231 keratocysts (OKC) were analyzed. Of these, 57 (24.7%) were treated by decompression and residual cystectomy, 86 (37.2%) by enucleation without adjuvant therapy and 78 (33.8%) by enucleation with peripheral ostectomy.
44 relapses were recorded with an average recurrence time of 26.7 months.  

CONCLUSIONS
From the data emerging from this study, which must be confirmed with other similar studies, it can be concluded that, using the appropriate time-to-event survival analysis, which also takes into account the cases lost to follow-up, 5 years after treatment of keratocysts has a cure rate without recurrence of 29%. Mandibular lesions, multilocular lesions and lesions treated by decompression and residual cystectomy were found to be more associated with recurrence.


For additional informations:
How well do we manage the odontogenic keratocyst? A multicenter study

Related articles

In a grand finale to an already record-breaking year, Viper Partners, the leading dealmaker in the dental industry, successfully closed three major oral surgery deals in the final week of 2023.


Ridge Oral Surgery has completed a major milestone as it celebrates its first-year anniversary.


U.S. Oral Surgery Management (USOSM) has partnered with eight new partner practices in seven states: California, Colorado, Oregon, Michigan, Mississippi, South Carolina, and Texas.


This scoping review and analysis were designed to assess the amount of time spent delivering photobiomodulation light therapy after dental extraction to improve postoperative pain and wound healing.


Butch Marino tapped as the new chief executive officer

Butch Marino is an entrepreneurial and relational executive with over three decades of health care experience, including corporate development and senior leadership within multi-state, multi-location...


Read more

Every year, thousands of American children are diagnosed with acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The disease begins in bone marrow, when immature cells...


News     16 April 2024

Spring Synergy Winners

The UF College of Dentistry notched a record turnout for its annual celebration of research – Spring Synergy – on Friday, March 29 at the HPNP Auditorium


Glidewell recently announced a rebrand of its flagship Hahn Tapered Implant System, now known as the Glidewell HT Implant System.


Zentist, the leading cloud-based insurance Revenue Cycle Management (RCM) software for U.S. dental groups, proudly announces the introduction of Cavi AR, an additional innovative solution that is...


Costas, Inc., operating as Standard Dental Labs Inc., a renowned name in the dental industry, is pleased to announce the filing of its annual report for the fiscal year ending 2023 on April 10th,...


 
 
 
 

 
 
 
 

Most popular

 
 

Events